The glycosylase base editor (GBE) could edit C to G in mammalian cells. However, the application of GBE was constrained by relatively low efficiency and targeting scope. More excellent strategies were expected to increase the efficiency and targeting scope for wider application of GBE in treatment of genomic disease.
In a study published inCell Reports, BI Changhao's lab and ZHANG Xueli's lab at Tianjin Institute of Industrial Biotechnology of the Chinese Academy ofSciences constructed enhancedGBE variants for wider application.
The optimized GBEs were obtained via integrating transactivation modules, SunTag-system and Cas9 variant.
Firstly, the transactivation modules were selected to fused to GBE, and the higher efficiency was obtained at all testing loci in HEK293T cells. In addition, the SunTag system was utilized to optimize the performance of GBE. The higher efficiency, higher purity and extended editing window were acquired. Finally, the SpRY-Cas9 was fused to GBE to construct the SpRY-GBE variant, which could recognize the non-NGG PAM and provide the wider targeting scope for GBE.
The GBE variants with superior performance were acquired, which provides wider application ofGBE for targeting more genomic sites with higher efficiency and specificity, thus improving the potential for the genetic therapy of more mutational related diseases
Working diagram of the SunTag-GBEs ( Image by TIBCAS)
Prof. BI Changhao
Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences.
32 West 7th Avenue, Tianjin Airport Economic Area, Tianjin 300308, China
Tel: 022-84861997/84861977 Fax: 022-84861926 E-mail: tib_zh(AT)tib.cas.cn
Copyright @2013, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences